Jinru Shia

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

102h-index35.3kcitations801works3.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic factors in colorectal cancer(247), Colorectal Cancer Treatments and Studies(216), Colorectal Cancer Surgical Treatments(115), Colorectal and Anal Carcinomas(115), Cancer Genomics and Diagnostics(109)

Publications799 total

Quo Vadis colorectal intramucosal adenocarcinoma?

Journal of Clinical Pathology·2026

ASO Visual Abstract: The Effect of Pathological Response to Preoperative Therapy on Margin Status and Outcomes After Resection of Colorectal Liver Metastases

Annals of Surgical Oncology·2026

A neural network model delivers a highly prognostic protein signature in cancer stem cells that identifies relapse in stage III colorectal cancer patients

2026

The Effect of Pathologic Response to Preoperative Therapy on Margin Status and Outcomes After Resection of Colorectal Liver Metastases

Annals of Surgical Oncology·2026

Changing landscape of multidisciplinary management in locally advanced rectal cancer (2015-2023).

Journal of Clinical Oncology·2026

Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

2025Open Access

Risk of Residual Cancer After Immediate Surgery or Nonoperative Management After Malignant Colorectal Polypectomy With High-Risk Features

JCO oncology advances.·2025Open Access

Supplementary Table S2 from The Impact of Germline Alterations in Appendiceal Adenocarcinoma

2025Open Access

Supplementary Figure S1 from The Impact of Germline Alterations in Appendiceal Adenocarcinoma

2025Open Access

Supplementary Table S1 from The Impact of Germline Alterations in Appendiceal Adenocarcinoma

2025Open Access

Supplementary Table S3 from The Impact of Germline Alterations in Appendiceal Adenocarcinoma

2025Open Access

Supplementary Figure S2 from The Impact of Germline Alterations in Appendiceal Adenocarcinoma

2025Open Access

page 1 of 40Next →

Frequent Co-authors

Martin R. Weiser(26), Leonard B. Saltz(23), Philip B. Paty(21), José G. Guillem(20), Zsofia K. Stadler(14), David S. Klimstra(14), Larissa K. Temple(13), Andrea Cercek(12), W. Douglas Wong(12), Neil H. Segal(11), Rona Yaeger(11), Mithat Gönen(11), Julio García‐Aguilar(10), Michael F. Berger(10), Jaclyn F. Hechtman(9), David B. Solit(9), Nancy E. Kemeny(8), Efsevia Vakiani(8), Garrett M. Nash(8), J. Joshua Smith(7)